What LISCure Biosciences does

LISCure Biosciences Inc. (리스큐어바이오사이언시스) is a clinical-stage South Korean pharmaceutical company founded in 2018–2019 and headquartered in Seongnam-si, Gyeonggi-do, with a regional subsidiary in Brisbane, Australia. The company develops microorganism-based medicines across two therapeutic modalities — injectable bacteria-mediated cancer immunotherapy (LB-P2D for solid tumors) and oral live biotherapeutic products (LB-P8 for PSC and MASH/MASLD, LB-P6 for autoimmune disease, LB-P4 and the Celltrion-co-developed LC-PC01/LC-PC02 for Parkinson's) — supported by the proprietary LMT (LISCure Microbiology-based Technology) platform that combines a 3,000+ strain microbiota bank, a 500+ genome microbiome database with machine learning, and disease-specific screening systems (LMT-ACE, LMT-MAX, LMT-AIR, LMT-NX).

Its product portfolio also includes ExoPN-101 (ExoPass-N), a next-generation BBB shuttle platform using microbial-derived extracellular vesicles to deliver ASO, siRNA, small molecules, peptides, and antibodies into the CNS. LISCure monetizes through a dual-track model: licensing out pharmaceutical pipeline assets (including BBB shuttle and LB-P8) to global pharma via Material Transfer Agreements leading to definitive licensing deals, and commercializing proprietary probiotic functional ingredients — Mobiome (hair health) and JointWorks (joint health), both world's-first KMFDS approvals — through licensing agreements with nutraceutical and functional food companies in domestic and global markets. Revenue from pharma is currently pre-commercial; functional ingredients generate early-stage commercial revenue.

LISCure holds multiple first-in-class regulatory designations including FDA Orphan Drug Designation (2022) and Fast Track Designation (2024) for LB-P8 in PSC, and the first-ever live biotherapeutic IND clearance for PSC (2024). It is actively preparing for an IPO in 2025–2026, has raised approximately $55–60M cumulatively across seed, Series B, and 2024–2026 private placements, and runs a global Phase 2 trial for LB-P8 across 28 US and European clinical sites in collaboration with Mayo Clinic, Scripps Research, and Celltrion.

Name

LISCure Biosciences

Legal name

LISCure Biosciences Inc. (리스큐어바이오사이언시스)

Website

https://liscure.bio

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

LISCure Biosciences is a clinical-stage South Korean biotech developing microbiome-based therapeutics — including live biotherapeutic products, bacterial cancer immunotherapy, and a BBB shuttle platform — while commercializing proprietary probiotic functional ingredients for global pharma and consumer health partners.

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK)

akta.pro secondary industries

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Microbiome therapeutics
• Live biotherapeutic products
• Bacterial immunotherapy
• Blood-brain barrier shuttle
• Probiotic functional ingredients

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Licensing Deals: LISCure licenses out its proprietary drug candidates and platform technologies (BBB shuttle, LB-P8, immuno-oncology programs) to global pharmaceutical companies through MTAs and definitive licensing agreements. Revenue is generated through upfront payments, milestone payments, and royalties.
2. Functional Health Ingredients: Commercialization of proprietary probiotic ingredients (e.g., Mobiome for hair health, JointWorks for joint health) as recognized health functional ingredients, sold to nutraceutical and functional food companies in domestic Korean market and globally. This is described as establishing a stable and sustainable revenue model alongside pharmaceutical R&D.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

LISCure Biosciences is a clinical-stage pharmaceutical company developing microorganism-based medicines through two main modalities: injectable bacteria-mediated cancer immunotherapy and oral microbiome therapeutics. The company leverages its proprietary LMT (LISCure Microbiology-based Technology) platform — combining a therapeutic screening system, a microbiota bank of 3,000+ microbial strains, and a microbiome database of 500+ genomes — to discover and develop live biotherapeutic products, bacterial immunotherapies, and a brain-targeted extracellular vesicle drug delivery system.

Product overview

LISCure Biosciences is a clinical-stage pharmaceutical company developing microorganism-based medicines through two main platforms: injectable bacteria-mediated cancer immunotherapy and oral microbiome therapeutics. Their product portfolio includes Live Biotherapeutic Products (LB-P8 for PSC/liver disease, LB-P6 for autoimmune diseases, LB-P4 and LC-PC01/LC-PC02 for neurodegenerative diseases), Bacterial Immunotherapy (LB-P2D for solid tumors), and a Brain-targeted Drug Delivery System (ExoPN-101 BBB shuttle). They also commercialize functional ingredients including JointWorks® for joint health and Mobiome® for hair health. Research collaborations include partnerships with Mayo Clinic, Scripps Research, and Celltrion.

Differentiator

Problem solved

Functional benefit

Brands

• ExoPN-101: Next-generation BBB (Blood-Brain Barrier) shuttle platform for brain-targeted drug delivery using extracellular vesicles derived from microbial cells.
• ExoPass-N
• LMT-ACE
• LMT-MAX
• LMT-AIR
• LMT-NX
• Mobiome
• JointWorks

Products and services

• LB-P8 Oral, once-daily live biotherapeutic product comprised of a single microbial strain targeting fibrosis and inflammation through the gut-liver axis. In Phase 2 for Primary Sclerosing Cholangitis (PSC) with demonstrated anti-fibrotic and anti-inflammatory effects in PSC, MASH, and IBD animal models. FDA Orphan Drug Designation (2022) and Fast Track Designation (2024) received.
• LB-P2D Novel injectable non-pathogenic bacterial immunotherapy for solid tumors (colorectal and pancreatic cancers) that activates antigen-presenting cells including dendritic cells and induces proliferation of tumor-specific T cells, converting cold tumors to hot tumors. Shows complete remission even with a single dose in animal studies.
• LB-P4 Live biotherapeutic product comprising a single microbial strain effective in neurodegenerative diseases including Parkinson's disease and Alzheimer's disease through the gut-brain axis.
• LB-P6 Live biotherapeutic product candidate for autoimmune diseases, part of LISCure's LMT-AIR screening program output.
• LC-PC01 Live biotherapeutic product targeting Parkinson's Disease developed in joint research with Celltrion (research collaboration ongoing since 2013).
• LC-PC02 Second live biotherapeutic product targeting Parkinson's Disease developed in joint research with Celltrion.
• ExoPN-101

Quantifiable outcome

• Mobiome demonstrated statistically significant improvements in hair glossiness, elasticity, and overall user satisfaction (p<0.05, 95% confidence level) across multiple hair-related parameters including texture, split ends, dryness, breakage, tangling, and damage in human clinical trials.
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Four partnerships are on record, tiered core.

• Global Pharmaceutical Company (4th MTA partner)coreStrategic or Co-development Partner · 13 November 2025Fourth Material Transfer Agreement signed with a leading global pharmaceutical company for the technology transfer evaluation of ExoPN-101, LISCure's proprietary BBB shuttle platform. Successful completion is expected to lead to negotiations for a definitive licensing-out agreement.
• CelltrioncoreStrategic or Co-development Partner · 21 February 2023Strategic collaboration for co-research and co-development of novel microbiome therapeutics. Joint research ongoing since 2013 to develop new live biotherapeutic products LC-PC01 and LC-PC02 targeting Parkinson's Disease.
• Scripps Research InstitutecoreStrategic or Co-development Partner · 3 February 2022Collaborative research agreement with The Scripps Research Institute for bacteria-mediated immuno-oncology candidates against multiple cancer types, focusing on LB-P2D injectable non-pathogenic bacterial immunotherapy program.
• Mayo CliniccoreStrategic or Co-development Partner · 6 January 2022Research collaboration agreement for new drug development for rare liver diseases including PSC, led by Nicholas F. LaRusso, M.D. and Steven P. O'Hara, Ph.D. Mayo Clinic and LISCure metabolic disease R&D teams collaborate on preclinical and clinical studies, recognizing importance of microbiome-based therapeutic approach for PSC.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined bacterial consortia as live biotherapeutic products for IBD, infectious disease, and immuno-oncology — closely comparable to LISCure's LBP pipeline in PSC and oncology indications.
• MaaT Pharma: French clinical-stage biotech developing microbiome-based therapies for inflammatory diseases and graft-versus-host disease, with a Phase 3 program in a hematology indication. Comparable to LISCure's LB-P8 in PSC and broader gut-liver axis strategy.
• Seres Therapeutics: Pioneer in microbiome therapeutics with the first FDA-approved microbiome therapeutic (Vowst) and an active pipeline in IBD and oncology. A direct LBP peer to LISCure's LB-P8 and LB-P2D programs.
• 4D pharma: UK-based clinical-stage microbiome company developing single-strain Live Biotherapeutic Products for cancer, respiratory disease, and CNS indications — directly analogous to LISCure's single-strain LBP approach across multiple therapeutic areas.
• Synlogic: Clinical-stage company developing Synthetic Biotics (engineered probiotic medicines) for rare metabolic diseases and oncology — comparable synthetic-biology-meets-microbiome modality with similar clinical-stage risk profile to LISCure.

Emerging players

• Federation Bio: Microbiome therapeutics company developing defined bacterial consortia with a focus on immuno-oncology and rare diseases — overlapping with LISCure's LB-P2D bacterial immunotherapy and rare liver disease focus.
• Eligo Bioscience: Pioneering phage-based microbiome therapeutics platform (Eligobiotics) — shares LISCure's bacteria-mediated therapeutic modality but uses phage-delivered payloads rather than live bacterial products.

Broad incumbents

• Denali Therapeutics: Larger publicly-traded biotech with a proprietary BBB delivery platform (ATV platform for enzyme and antibody transport across the BBB) — a broader incumbent with comparable brain-shuttle platform technology to LISCure's ExoPN-101.
• Celltrion: Korea's largest biopharmaceutical company, established LISCure research partner since 2013 for Parkinson's Disease LBPs (LC-PC01, LC-PC02). Acts as both a strategic partner and a broader regional incumbent in biosimilars/biologics who could acquire LISCure at scale.

Regional players

• iNtRON Biotechnology: Korean clinical-stage biotech developing bacteriophage and microbiome-based therapeutics — a Korea-based peer with comparable modality and investor overlap (existing LISCure investor).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LISCure Biosciences